Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 29;10(13):2885.
doi: 10.3390/jcm10132885.

Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study

María Chaparro  1 , Ana Garre  1 , Andrea Núñez Ortiz  2 , María Teresa Diz-Lois Palomares  3 , Cristina Rodríguez  4 , Sabino Riestra  5 , Milagros Vela  6 , José Manuel Benítez  7 , Estela Fernández Salgado  8 , Eugenia Sánchez Rodríguez  9 , Vicent Hernández  10 , Rocío Ferreiro-Iglesias  11 , Ángel Ponferrada Díaz  12 , Jesús Barrio  13 , José María Huguet  14 , Beatriz Sicilia  15 , María Dolores Martín-Arranz  16 , Xavier Calvet  17 , Daniel Ginard  18 , Inmaculada Alonso-Abreu  19 , Luis Fernández-Salazar  20 , Pilar Varela Trastoy  21 , Montserrat Rivero  22 , Isabel Vera-Mendoza  23 , Pablo Vega  24 , Pablo Navarro  25 , Mónica Sierra  26 , José Luis Cabriada  27 , Mariam Aguas  28 , Raquel Vicente  29 , Mercè Navarro-Llavat  30 , Ana Echarri  31 , Fernando Gomollón  32 , Elena Guerra Del Río  33 , Concepción Piñero  34 , María José Casanova  1 , Katerina Spicakova  35 , Jone Ortiz de Zarate  36 , Emilio Torrella Cortés  37 , Ana Gutiérrez  38 , Horacio Alonso-Galán  39 , Álvaro Hernández-Martínez  40 , José Miguel Marrero  41 , Rufo Lorente Poyatos  42 , Margalida Calafat  43 , Lidia Martí Romero  44 , Pilar Robledo  45 , Orencio Bosch  46 , Nuria Jiménez  47 , María Esteve Comas  48 , José María Duque  49 , Ana María Fuentes Coronel  50 , Manuela Josefa Sampedro  51 , Eva Sesé Abizanda  52 , Belén Herreros Martínez  53 , Liliana Pozzati  54 , Hipólito Fernández Rosáenz  55 , Belén Crespo Suarez  56 , Pilar López Serrano  57 , Alfredo J Lucendo  58   59   60 , Margarita Muñoz Vicente  61 , Fernando Bermejo  62 , José Joaquín Ramírez Palanca  63 , Margarita Menacho  64 , Amalia Carmona  65 , Raquel Camargo  66 , Sandra Torra Alsina  67 , Nuria Maroto  68 , Juan Nerín de la Puerta  69 , Elena Castro  70 , Ignacio Marín-Jiménez  71 , Belén Botella  72 , Amparo Sapiña  73 , Noelia Cruz  74 , José Luis F Forcelledo  75 , Abdel Bouhmidi  76 , Carlos Castaño-Milla  77 , Verónica Opio  78 , Isabel Nicolás  79 , Marcos Kutz  80 , Alfredo Abraldes Bechiarelli  81 , Jordi Gordillo  82 , Yolanda Ber  83 , Yolanda Torres Domínguez  84 , María Teresa Novella Durán  85 , Silvia Rodríguez Mondéjar  86 , Francisco J Martínez-Cerezo  87 , Lilyan Kolle  88 , Miriam Sabat  89 , Cesar Ledezma  90 , Eduardo Iyo  91 , Óscar Roncero  92 , Rebeca Irisarri  93 , Laia Lluis  94 , Isabel Blázquez Gómez  95 , Eva María Zapata  96 , María José Alcalá  97 , Cristina Martínez Pascual  98 , María Montealegre  99 , Laura Mata  100 , Ana Monrobel  101 , Alejandro Hernández Camba  102 , Luis Hernández  103 , María Tejada  104 , Alberto Mir  105 , María Luisa Galve  106 , Marta Soler  107 , Daniel Hervías  108 , José Antonio Gómez-Valero  109 , Manuel Barreiro-de Acosta  11 , Fernando Rodríguez-Artalejo  110 , Esther García-Esquinas  110 , Javier P Gisbert  1 ; The EpidemIBD Study Group Of Geteccu
Collaborators, Affiliations

Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study

María Chaparro et al. J Clin Med. .

Erratum in

  • Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. J. Clin. Med. 2021, 10, 2885.
    Chaparro M, Garre A, Núñez Ortiz A, Diz-Lois Palomares MT, Rodríguez C, Riestra S, Vela M, Benítez JM, Fernández Salgado E, Sánchez Rodríguez E, Hernández V, Ferreiro-Iglesias R, Ponferrada Díaz Á, Barrio J, Huguet JM, Sicilia B, Martín-Arranz MD, Calvet X, Ginard D, Alonso-Abreu I, Fernández-Salazar L, Varela Trastoy P, Rivero M, Vera-Mendoza I, Vega P, Navarro P, Sierra M, Cabriada JL, Aguas M, Vicente R, Navarro-Llavat M, Echarri A, Gomollón F, Guerra Del Río E, Piñero C, Casanova MJ, Spicakova K, Ortiz de Zarate J, Torrella Cortés E, Gutiérrez A, Alonso-Galán H, Hernández-Martínez Á, Marrero JM, Lorente Poyatos R, Calafat M, Martí Romero L, Robledo P, Bosch O, Jiménez N, Esteve Comas M, Duque JM, Fuentes Coronel AM, Josefa Sampedro M, Sesé Abizanda E, Herreros Martínez B, Pozzati L, Fernández Rosáenz H, Crespo Suarez B, López Serrano P, Lucendo AJ, Muñoz Vicente M, Bermejo F, Ramírez Palanca JJ, Menacho M, Carmona A, Camargo R, Torra Alsina S, Maroto N, Nerín de la Puerta J, Castro E, Marín-Jiménez I, Botella B, Sapiña A, Cruz N, Forcelledo JLF, Bouhmidi A, Castaño-Milla C, Opio V, Nicolás I, Kutz M, Abraldes Bechiarelli A, Gordillo J, Ber Y, Torres Domínguez Y, Novella Durán … See abstract for full author list ➔ Chaparro M, et al. J Clin Med. 2022 Sep 30;11(19):5816. doi: 10.3390/jcm11195816. J Clin Med. 2022. PMID: 36233844 Free PMC article.

Abstract

(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD-Crohn's disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)-during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100,000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31-56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery.

Keywords: Crohn’s disease; epidemiology; incidence; inflammatory bowel disease; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

M.C. has served as a speaker, or has received research or education funding from MSD, Abbvie, Hospira, Pfizer, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Phar-ma. J.M.B. has served as a speaker, a consultant and advisory member or has received research or education funding from Dr. Falk Pharma, Faes Farma, Ferring, Shire Pharmaceuticals, MSD, Abbvie, Takeda and Janssen. F.G. has received fees for educational activities and grants to attend conferences from Janssen, Takeda, Abbvie and MSD. His group receives research funding from MSD, Abbvie, Janssen, Takeda, and Tillots. J.M.D.A. has received grants to attend conferences from MSD, ABBVIE, Takeda, Falk. M Rivero as served as a speaker, a consultant and an advisory member for MSD, Abbvie, Janssen and Pfizer. R.F.-I. has served as a speaker for or has received research funding from Takeda, MSD, Abbvie, Janssen, Palex, Shire Pharmaceuticals, Til-lottsPharma. V.H. has served as speaker, has received travel support or research funding from MSD, AbbVie, Ferring, FAES Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Otsuka Pharmaceutical, Pfizer, Takeda, Jansen, KernPharma Biologics, Gebro Pharma, Adacyte, Sandoz and Biogen. I.M.-J. has served as a speaker, consultant or advisory board member for Abbvie, Amgen, Biogen, Celltrion, Fresenius, Ferring, Dr. Falk Pharma, Hospira, Janssen, MSD, Otsuka Pharmaceutical, Pfizer, Sandoz, Shire Pharmaceuticals, Takeda and Tillotts Pharma. M.J.C. has received education funding from Pfizer, Takeda, Janssen, MSD, Ferring and Abbvie MD M.A. has received fees as a speaker, consultant and advisory member for and has received research funding from MSD, AbbVie, Hospira, Pfizer, Takeda, Janssen, Shire Pharmaceuticals, Tillotts Pharma, Faes Pharma. I.V. has served as speaker, consultant and advisory member for and has received funding from MSD, Abbvie, Pfizer, Ferring, Shire Pharmaceuticals, Takeda and Jannsen. I.N. has received fees as a speaker from Takeda and Janssen. J.P.G. has served as a speaker, a consultant and advisory member for or has received research funding from MSD, Abbvie, Hospira, Pfizer, Kern Pharma, Biogen, Takeda, Janssen, Roche, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Vifor Pharma. Rest of authors have nothing to declare.

Figures

Figure 1
Figure 1
Incidence of inflammatory bowel disease (A), Crohn’s disease (B) and ulcerative colitis (C) by Autonomous Communities in Spain in 2017 (cases/100,000 person-years).
Figure 2
Figure 2
Cumulative incidence of exposure to mesalamine (1), systemic steroids (2), immunomodulators (3), biologics (4) and surgery (5) in Crohn’s disease (CD), ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBD-U) during 1-year follow-up.
Figure 3
Figure 3
Cumulative incidence of treatments in Crohn’s disease (CD) based on hospital categories: lower resources (1 and 2) vs. higher resources (3–5).
Figure 4
Figure 4
Cumulative incidence of treatments in ulcerative colitis based on hospital categories: low resources (1 and 2) vs. higher resources (3–5).
See this image and copyright information in PMC

References

    1. Kaplan G.G. The global burden of IBD: From 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 2015;12:720–727. doi: 10.1038/nrgastro.2015.150. - DOI - PubMed
    1. Ng S.C., Shi H.Y., Hamidi N., Underwood F.E., Tang W., Benchimol E.I., Panaccione R., Ghosh S., Wu J.C.Y., Chan F.K.L., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 2018;390:2769–2778. - PubMed
    1. Coward S., Clement F., Benchimol E.I., Bernstein C.N., Avina-Zubieta J.A., Bitton A., Carroll M.W., Hazlewood G., Jacobson K., Jelinski S., et al. Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. Gastroenterology. 2019;156:1345–1353. doi: 10.1053/j.gastro.2019.01.002. - DOI - PubMed
    1. Peyrin-Biroulet L., Sandborn W., Sands B.E., Reinisch W., Bemelman W., Bryant R.V., D’Haens G., Dotan I., Dubinsky M., Feagan B., et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am. J. Gastroenterol. 2015;110:1324–1338. doi: 10.1038/ajg.2015.233. - DOI - PubMed
    1. Targownik L.E., Kaplan G.G., Witt J., Bernstein C.N., Singh H., Tennakoon A., Zubieta A.A., Coward S.B., Jones J., Kuenzig M.E., et al. Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population-Based Analysis. Am. J. Gastroenterol. 2020;115:128–137. doi: 10.14309/ajg.0000000000000503. - DOI - PubMed